Morning Trading February 28, page-172

Can we use the drug on politicians as they all appear to have significant brain injury?

Nyrada’s brain injury drug shows efficacy

Nyrada’s (ASX:NYR)leadBrain Injury Programdrug candidate,NYR-BI03, has demonstrated strong efficacy in reducing injury in a preclinical study in animals.

The study showed a significant neuroprotective signal, providing strong evidence of efficacy for the drug.

Conducted in collaboration with UNSW Sydney, the study involved 16 test animals, which were treated with either NYR-BI03 or vehicle, 30 minutes following induced brain injury, with treatment conducted for 72 hours via continuous intravenous infusion.

The MRI brain imaging results showed that a statistically significant neuroprotection was achieved when animals received NYR-BI03 treatment.

On average, NYR-BI03 therapy rescued 42% of the brain injury in the penumbra region seen in animals receiving vehicle.

Nyrada will now move on to Phase I clinical trial in humans, which is scheduled for the second half of the 2024 calendar year.